IVA Inventiva - ADR

Piper Sandler reit'd $IVA Overweight-$26/said We had the opportunity to host IVA for a well-attended investor dinner in NYC. $MDGL $LLY NVO VKTX SGMT ALGS Piper Sandler added—Accordingly, we walked away with reinforced confidence in lanifibranor's Ph3 NATIV3 topline 4Q26 to hit stat sig on its composite primary endpoint which mitigates high placebo responses and is de-risked by the 24% placebo-adjusted improvement observed in Ph2b NATIVE. With that, recognize the bogey is for lanifibranor to recapitulate the findings of NATIVE and demonstrate an 18% placebo-adjusted improvement on ≥1-stage fibrosis without worsening of MASH. Further, note lanifibranor represents a differentiated asset as a panPPAR agonist which offers both intra- and extra- hepatic effects to drive comprehensive benefits in MASH with substantially reduced risk of fluid retention and weight gain. Ultimately, we remain bullish on IVA and believe now is the time to own ahead of this potentially major stock-moving event in 4Q26.

Guggenheim⬆️ $IVA's PT to $14 and reiterated Buy. $MDGL $LLY NVO ALGS SGMT VKTX Guggenheim said in its note: In our second report, we highlight our proprietary stats analysis alongside our conversations with mgmt that support a high likelihood of success at the 1200mg dose that are maintained across a variety of stress tests. We estimate a > 90% probability of a positive p < 0.02 result and the probability that lanifibranor 1200mg achieves a pbo-adjusted effect size at least comparable to Rezdiffra at >70%. Accordingly, we are updating both our scenario expectations ahead of NATIV3 and our lanifibranor for recent market trends, which raises our PT to $14/shr (from $11/shr previously).

$IVA During today’s webcast, the CEO concluded with the following statement: “I think the next time we talk will be on the data release.” At least that’s clear!

$IVA Data make or break ver soon. expect chatter to increase around this stock very soon. potentially a target for $NVO or $LLY

$IVA Truist IVA – Preview of the company-defining NATiV3 results. New PT of $18/share vs. $13/share. Ahead of the NATiV3 Phase 3 data for lani in MASH expected in Q4 2026, Truist reiterates its Buy rating on IVA with a new price target of $18/share, up from $13/share previously. Following an in-depth analysis of the Phase 2b data, the assumptions underpinning the Phase 3 trial, and management’s comments

$IVA — the fibrosis bet Taking a SCOUT position here Lanifibranor (pan-PPAR) NATiV3 Ph3 topline → Q4 2026. LPLV done Sep 2. Why fibrosis is the whole thesis: Ph2b NATIVE (NEJM) hit BOTH — MASH resolution AND ≥1-stage fibrosis improvement. First drug ever to do both in one trial. That's the edge. The trap: MASH resolution alone ≠ approval. Regulators want fibrosis. Watch that endpoint, not the headline. Not advice. Just my thesis.

Truist reiterated $IVA Buy-$13 and said -- We remain buyers of IVA following EPS call & ahead of Ph3 NATIV3 data (4Q26) for lani in MASH. $MDGL LLY $NVO SGMT VKTX ALGS Truist added—Our conviction in IVA is supported by – 1) Large market opportunity with 2 drugs approved & unmet need in a heterogeneous MASH population; 2) Strong Ph2 data which showed 18% pbo-adjusted fibrosis improvement at 6-mo with potential to see deepening of response at 18-mo endpoint; & 3) KOL checks indicating low rates of weight-gain/edema being manageable and potentially outweighed by significant fibrosis and cardiometabolic improvements; we do acknowledge the latter as an investor overhang. If NATIV3 is positive, we see NDA filing in 1H27 and 2028 US commercial launch. Reiterate Buy.

Kickstarting a conversation as $IVA NATiV3 gets closer. Would genuinely love to hear the bear case, particularly from $MDGL and $NVO followers. My current thinking: • Weight gain: clearly a liability. But Phase 2 suggests the gain was metabolically different from conventional weight gain, while insulin resistance, lipids and liver markers improved. There is also human evidence that combining lanifibranor with an SGLT2 can neutralise the weight gain. GLP-1 combination potential is interesting, not proven tho • Oedema: real, but mostly mild in Phase 2. Phase 3 needs to confirm that over much longer exposure. • Anaemia: probably the safety issue I understand least. 7% at 1200 mg in NATIVE, reversible. • The bull case: fibrosis. If NATiV3 reproduces the strength of the Phase 2 fibrosis signal alongside the broader metabolic/T2D effects, I struggle to see lanifibranor as simply another $MDGL/$NVO competitor. It may occupy a rather different place in MASH treatment. What am I missing?

$IVA will be added to the SBF 120. Euronext announced on September 10, 2026 the addition of Inventiva and Genfit to the SBF 120 as well as to the CAC Mid 60. The change will be implemented after market close on Friday, September 18, and will take effect on Monday, September 21, 2026.

$IVA October is still too early for a P3 readout announcement. I have a feeling it's gonna be by mid-November. The current volatility is due to the anticipation of Q3 earnings and just the nature of a very binary biotech event.

$IVA TOOTs have major investments in this hidden. Do you see any toots selling? I’m trying to figure out why it’s going down

$IVA hello friends, I was full in $GALT but made a move yesterday to join the $IVA believers. Doubting of selling all my shares of Galt and move to here. Any thoughts?

$IVA Quote from the article below: "Obenshain said the company is open to acquisition interest, but its current plan is to launch independently. “We are building the company to do it ourselves,” he said." Interpretation: We want to be acquired for a price that is good for us and out share holders.

$IVA stated its interim financial report for the first half of 2026, with unaudited results and a corporate presentation.

$IVA Data Q4? Or did I get my signals crossed? Any hint at a data/month? Still believe $IVA is the best near-term liver play. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money.

$IVA Stifel has some splainin to support their wacko $15 lottery ticket price target Gimme a break This will be bk in a year

$IVA may have just become a much more interesting name to watch. Forget generic biotech M&A. Look specifically at Novo. Novo just told investors: • it will be more active in BD • its balance sheet can support larger acquisitions • deal size is NOT the starting point, asset quality is • liver disease is becoming a strategic growth pillar • even after Wegovy + efruxifermin + UBT251, Novo says it wants further novel mechanisms Now look at what is approaching: $IVA Lanifibranor Oral pan-PPAR Phase 3 MASH F2/F3 Metabolic + inflammatory + antifibrotic biology NATiV3 readout approaching Novo already spent up to $5.2B to acquire Akero and establish itself deeper in MASH. If NATiV3 produces genuinely strong fibrosis data, the question around $IVA may change very quickly from: “Does lanifibranor work?” to: “What is a differentiated, Phase 3-ready/validated MASH asset worth to a company determined to build a liver franchise?” No claim Novo buys Inventiva. NFA. DYOR.